Last reviewed · How we verify
MET-3
At a glance
| Generic name | MET-3 |
|---|---|
| Also known as | MET-5 |
| Sponsor | NuBiyota |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Step Down FSH Approach and Late Follicular Phase in Progesterone Level (EARLY_PHASE1)
- Safety and Efficacy of MET-3 in Obese Human Subjects (EARLY_PHASE1)
- Effects of MET-3 and MET-5 on Gut Microbiome and Metabolic Function in Men and Women With Hypertriglyceridemia (PHASE1)
- Effects of Autogenic and Reciprocal Inhibition, Muscle Energy Techniques in the Management of Mechanical Neck Pain (NA)
- The Efficacy of Using Volunteers to Implement a Cognitive Stimulation Program in Two Long-Term Care Homes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MET-3 CI brief — competitive landscape report
- MET-3 updates RSS · CI watch RSS
- NuBiyota portfolio CI